Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

被引：0

作者：

Joyce O’Shaughnessy

Adam Brufsky

Hope S. Rugo

Sara M. Tolaney

Kevin Punie

Sagar Sardesai

Erika Hamilton

Delphine Loirat

Tiffany Traina

Roberto Leon-Ferre

Sara A. Hurvitz

Kevin Kalinsky

Aditya Bardia

Stephanie Henry

Ingrid Mayer

Yanni Zhu

See Phan

Javier Cortés

机构：

[1] Texas Oncology-Baylor Charles A. Sammons Cancer Center,Medical Oncology

[2] University of Pittsburgh Medical Center,Magee

[3] University of California San Francisco Helen Diller Family Comprehensive Cancer Center,Womens Hospital and the Hillman Cancer Center

[4] Dana-Farber Cancer Institute,Department of Medicine

[5] Leuven Cancer Institute,Medical Oncology

[6] University Hospitals Leuven,Department of General Medical Oncology and Multidisciplinary Breast Centre

[7] The Ohio State University Comprehensive Cancer Center,Medical Oncology Department and D3i

[8] Sarah Cannon Research Institute/Tennessee Oncology,Department of Oncology

[9] Institut Curie,Medical Oncology

[10] Memorial Sloan Kettering Cancer Center,Department of Hematology/Oncology

[11] Mayo Clinic,Department of Oncology

[12] University of California,Hematology, Radiotherapy, and Nuclear Medicine

[13] Los Angeles,Breast Cancer Program, Division of Hematology/Oncology

[14] Jonsson Comprehensive Cancer Center,Department of Biostatistics

[15] Columbia University Irving Medical Center,Department of Clinical Development

[16] Massachusetts General Hospital Cancer Center,International Breast Cancer Center

[17] Harvard Medical School,undefined

[18] CHU UCL Namur,undefined

[19] Vanderbilt-Ingram Cancer Center,undefined

[20] Gilead Sciences,undefined

[21] Inc.,undefined

[22] Gilead Sciences,undefined

[23] Inc.,undefined

[24] Quironsalud Group,undefined

[25] Winship Cancer Institute,undefined

[26] Emory University,undefined

来源：

Breast Cancer Research and Treatment | 2022年 / 195卷

关键词：

Sacituzumab govitecan; Antibody–drug conjugate; Cyclin-dependent kinase inhibitor;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：127 / 139

页数：12

共 50 条

[31] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
Sathe, Abhishek G.
Singh, Indrajeet
Singh, Pratap
Diderichsen, Paul M.
Wang, Xiaohui
Chang, Peter
Taqui, Atiya
Phan, See
Girish, Sandhya
Othman, Ahmed A.
CLINICAL PHARMACOKINETICS, 2024, 63 (05) : 669 - 681
[32] Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors
Abhishek G. Sathe
Indrajeet Singh
Pratap Singh
Paul M. Diderichsen
Xiaohui Wang
Peter Chang
Atiya Taqui
See Phan
Sandhya Girish
Ahmed A. Othman
Clinical Pharmacokinetics, 2024, 63 : 669 - 681
[33] Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities
Spring, Laura M.
Nakajima, Erika
Hutchinson, Jennifer
Viscosi, Elene
Blouin, Gayle
Weekes, Colin
Rugo, Hope
Moy, Beverly
Bardia, Aditya
ONCOLOGIST, 2021, 26 (10): : 827 - 834
[34] New Data for Sacituzumab Govitecan-hziy in the Treatment of Metastatic Triple-Negative Breast Cancer
Bardia, Aditya
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 723 - 725
[35] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
Banys-Paluchowski, M.
Krawczyk, Natalia
ONKOLOGE, 2021, 27 (03): : 287 - 290
[36] Sacituzumab govitecan in triple-negative breast cancer: from bench to bedside, and back
Rossi, Valentina
Turati, Alessandra
Rosato, Antonio
Carpanese, Debora
FRONTIERS IN IMMUNOLOGY, 2024, 15
[37] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
不详
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
[38] Impact of UGT1A1 status on the safety profile of sacituzumab govitecan in the phase 3 ASCENT study in patients with metastatic triple-negative breast cancer
Rugo, Hope S.
Tolaney, Sara M.
Loirat, Delphine
Punie, Kevin
Bardia, Aditya
Hurvitz, Sara A.
O'Shaughnessy, Joyce
Cortes, Javier
Dieras, Veronique
Carey, Lisa
Gianni, Luca
Piccart, Martine J.
Loibl, Sibylle
Goldenberg, David M.
Hong, Quan
Olivo, Martin
Itri, Loretta M.
Kalinsky, Kevin
CANCER RESEARCH, 2021, 81 (04)
[39] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
Schoellmann, Claudia
BREAST CARE, 2022, 17 (01)
[40] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
Chen, Jigang
Han, Mingyang
Liu, Aihua
Shi, Bo
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →